Postinflammatory hyperpigmentation - Hyperpigmentation Postinflammatory
Ko te Hyperpigmentation Postinflammatory (Postinflammatory hyperpigmentation) he mate kiri e tohuhia ana e te pikinga o te poaka i roto i te kiri i muri i te mumura o te kiri. hyperpigmentation postinflammatory (postinflammatory hyperpigmentation) ka puta mai i te wa roa o te ra, te mumura, me etahi atu whara kiri, tae atu ki era e pa ana ki te hakihaki. Ko nga tangata he kiri pouri te nuinga o te waa ka kaha ake te paheketanga ki te nui o te ra.
☆ I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
References
Ko te Postinflammatory hyperpigmentation (PIH) he raruraru kiri auau ka puta i muri i te mumura kiri, i te whara ranei. He roa te wa, he kino rawa atu ki nga tangata he kiri pouri ake (Fitzpatrick skin types III–VI) . Ahakoa he maha nga wa ka pai ake i a ia ano, ka roa pea tenei, na reira ka hiahiatia te maimoatanga mo te wa roa. Ko te whakakotahi i nga maimoatanga rereke ka pai ake.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
